Biofield Expands Arsenal of Non-Invasive Diagnostic Devices
News Feb 09, 2009
Biofield Corp. has announced that it has acquired additional products for its portfolio of non-invasive cancer diagnostic products. Specifically, Biofield has acquired the exclusive worldwide distribution rights outside of Belgium, for ValiRx plc’s Human Papilloma Virus (HPV) diagnostic test for cervical cancer as well as for ValioRx’s HyperGenomics™ and Nucleosomic™ cancer diagnostics products.
The Company has also announced that is has opened an office in Bangalore, India where it is has been preparing to begin marketing the oral herpes device pursuant to the exclusive worldwide distribution rights it acquired from NeuroMed, as previously announced.
The company expects to begin marketing the device through a wholly owned Indian subsidiary, via direct web based/internet marketing, retail, wholesale and through physicians and hospitals within the next 30 days.
Shepard G. Bentley, the Company’s Chief Executive Officer, stated: “We are very pleased to be able to add a HPV diagnostic test for cervical cancer as well as ValioRx’s HyperGenomics™ and Nucleosomics™ cancer diagnostics products to our portfolio. When combining these products with those which we acquired pursuant to an exclusive worldwide distribution agreement with NeuroMed Devices, Inc. for the treatment of oral and genital herpes, with our own proprietary BDS, we are extremely well positioned to provide a broad range of non-invasive products and services.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.